Canakinumab successfully managed steroid-dependent idiopathic recurrent pericarditis in a child following an anaphylactic reaction to anakinra.
Case Report (n=1)
Does canakinumab successfully treat steroid-dependent idiopathic recurrent pericarditis in a patient with anaphylaxis to anakinra?
Canakinumab can be successfully used to manage steroid-dependent idiopathic recurrent pericarditis in children who experience anaphylaxis to anakinra.
Conventional algorithm for treatment of pericarditis and prevention of recurrences consists of non-steroid anti-inflammatory drugs and/or colchicine, followed by corticosteroids in resistant patients. Anakinra has emerged as a promising and safe treatment modality for steroid-dependent idiopathic recurrent pericarditis. However, the efficacy and safety of canakinumab, another anti-interleukin-1 agent, has not been assessed up to date. Herein, we present development of an anaphylactic reaction due to anakinra and a successful subsequent treatment with canakinumab for the first time in the literature.
Epçaçan et al. (Mon,) conducted a case report in steroid-dependent idiopathic recurrent pericarditis (n=1). canakinumab was evaluated on successful management of pericarditis. Canakinumab successfully managed steroid-dependent idiopathic recurrent pericarditis in a child following an anaphylactic reaction to anakinra.